Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2022

Ricciuti Biagio, Arbour Kathryn C, Lin Jessica J, Vajdi Amir, Vokes Natalie, Hong Lingzhi, Zhang Jianjun, Tolstorukov Michael Y, Li Yvonne Y, Spurr Liam F, Cherniack Andrew D, Recondo Gonzalo, Lamberti Giuseppe, Wang Xinan, Venkatraman Deepti, Alessi Joao V, Vaz Victor R, Rizvi Hira, Egger Jacklynn, Plodkowski Andrew J, Khosrowjerdi Sara, Digumarthy Subba, Park Hyesun, Vaz Nuno, Nishino Mizuki, Sholl Lynette M, Barbie David, Altan Mehmet, Heymach John V, Skoulidis Ferdinandos, Gainor Justin F, Hellmann Matthew D, Awad Mark M

Abstract excerpt

INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
AMP-Activated Protein Kinase Kinases
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Kelch-Like ECH-Associated Protein 1

NF-E2-Related Factor 2

Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34740862
DOI: 10.1016/j.jtho.2021.10.013
PMCID: PMC10980559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.PMID 34740862Read ↗

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).Semantic proximity Read ↗

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.Semantic proximity Read ↗

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.Semantic proximity Read ↗

<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity Read ↗

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.Semantic proximity Read ↗

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.Semantic proximity Read ↗

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Semantic proximity Read ↗

STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC.Semantic proximity Read ↗

Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Semantic proximity Read ↗

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.Semantic proximity Read ↗

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.